Abraxis BioScience, Inc. (NSDQ: ABII) received SFDA approval for ABRAXANE® Paclitaxel for Injection (Albumin Bound) as a breast cancer treatment. The approval was based on trials conducted in the US and in China. ABRAXANE is a protein-bound chemotherapy, combining paclitaxel and albumin to deliver the drug. Because the delivery mechanism does not require solvents, a 49% higher dose of the active ingredient, paclitaxel, can be given without causing safety issues. More details...

Stock Symbol: (NSDQ: ABII) (NYSE: AZN)